– CNBC
FDA Places Clinical Hold On Denali’s Alzheimer’s Potential Program
The FDA has issued a clinical hold on Denali Therapeutics Inc's (NAS
Related Posts
Oppenheimer Maintains Outperform on DraftKings, Lowers Price Target to $24
Oppenheimer analyst Jed Kelly maintains DraftKings (NASDAQ:DKNG) with a Outperform and lowers the price target from $32 to $24.
Deutsche Bank Maintains Buy on Burlington Stores, Lowers Price Target to $235
Deutsche Bank analyst Paul Trussell maintains Burlington Stores (NYSE:BURL) with a Buy and lowers the price target from $241 to $235.
